Kulkarni Samarth

CEO Kulkarni Samarth sold 9,798 shares of CRSP at $52.80 on 2026-03-11, stock now down -36.4% from 52-week high at $48.87.

Kulkarni Samarth, CEO, sold 9,798 shares at $52.80, reducing his position by 4.0% to 235.6K shares. The sale occurred at a price 8.1% above the current market price of $48.87, and notably the stock has declined -36.4% from its 52-week high of $76.78. CRSP's fundamentals are deteriorating: the company reported -90.6% annual revenue decline with quarterly revenue of $889.0K and a net loss of $106.4M. Across his cross-ticker track record, the insider has executed 20 prior sales with a 100.00% well-timed rate at the 90-day mark (averaging -17.5% 90-day returns after sells). At CRSP specifically, his prior two measurable sales both exhibited negative 90-day returns (-22.6% and -9.7%), indicating a consistent pattern of selling before subsequent declines in this security.

CEO Kulkarni sells 90,000 CRSP shares across 3 trades (Jan 20–22) for $5.2M at blended avg $57.40; holdings drop 40.1% to 134.2K shares.

Kulkarni executed 3 separate sales totaling 90,000 shares for $5,166,297.83, reducing his stake by 40.1% from 224.2K to 134.2K shares. The multi-day execution (Jan 20–22) across three distinct price points ($51.61, $52.10, $60.23) occurred in the context of the stock trading near its 52-week high at the time of the highest-priced tranche ($60.23 on Jan 22). At CRSP specifically, Kulkarni's prior 5 trades all achieved negative 90-day returns, with a 100% well-timed rate at this ticker. Fundamentals show a severely strained business model: annual revenue growth of -90.0%, latest-quarter revenue of only $889,000.00, and full-year net income of $-106,441,000.00. The CEO's substantial reduction in holdings amid deep operating losses and a dramatic revenue contraction represents a material shift in his equity exposure to the company.

CRSP CEO Kulkarni sells 50,895 shares for $3.5M; 4 of 4 prior CRSP sells were well-timed; co. revenue off -90.0% YoY, $892K last qtr, unprofitable.

Samarth Kulkarni, CEO of CRSP, sold 50,895 shares at $67.91 on 2025-10-17, reducing his holdings by 16.7% to 254.2K shares. His prior trade history at CRSP shows a strong execution pattern: all 4 of 4 prior sells were well-timed at the 90-day mark, with the most recent (2025-02-19) followed by a 90-day return of -25.7%, indicating the stock declined after his sales. His cross-ticker track record also shows 100.00% well-timed rate across 20 prior sells, though with an average 90-day return of -19.3%. Against this context of demonstrated timing accuracy, the current sale occurs as CRSP faces severe operational headwinds: revenue contracted 90.0% year-over-year to just $892K in the latest quarter, net income was negative $208.5M, and the company remains unprofitable over its most recent full fiscal year. While CRSP trades near its 52-week high (only -3.7% from the peak of $76.78), the fundamental deterioration combined with his consistent pattern of selling before declines warrants investor attention to the underlying business trajectory.

CRSP CEO sells 13,081 shares at $58.15; stock now $54.16 (-20.5% from 52-week high). All 5 prior CRSP sales well-timed.

Samarth Kulkarni, CRSP's CEO, sold 13,081 shares (13.1K shares) on 2025-08-18 at $58.15, reducing his stake by 5.9% to 207,004 shares (207.0K shares). The stock has since declined to $54.16 and is -20.5% from its 52-week high of $68.14, with a 30-day decline of -16.8%. Critically, all 5 of Kulkarni's prior open-market sales at CRSP were well-timed—each showing negative 90-day returns after execution—and his cross-ticker track record demonstrates a 100.00% well-timed sell rate across 20 prior sales with an average 90-day return of -18.9%. Against this backdrop of consistent prescience, the company's fundamentals are deeply troubled: annual revenue contracted -90.0% to $892,000.00 (latest quarter), net income is $-208,549,000.00 (the company is unprofitable), and market cap stands at $4,925,874,909.68. The insider's sale timing and the company's operational deterioration align as mutually reinforcing signals warrant close investor scrutiny of CRSP's near-term trajectory.

CEO Kulkarni sells 14,435 shares (7.2% of holdings) for $616,348.50 across two trades at $42.42–$43.32.

Samarth Kulkarni, CEO of CRISPR Therapeutics AG (CRSP), executed two separate open-market sales on 2025-03-11 and 2025-03-12, totaling 14,435 shares at a blended average price of $42.70, reducing his holdings from 199,863 to 185,428 shares (a 7.2% reduction). This sale occurs amid significant fundamental headwinds: the company reported annual revenue growth of -90.0% and remains deeply unprofitable with quarterly revenue of $602,000 and a net loss of $-85,942,000. The timing is notable relative to Kulkarni's historical pattern: his prior two measurable sales at CRSP both proved well-timed (negative 90-day returns of -28.4% and -20.3%), and his cross-ticker track record shows a 100.00% well-timed rate on 20 prior sells with an average 90-day return of -18.9%. The stock has declined 4.2% over the last 90 days and trades 45.2% below its 52-week high, though it has risen 10.4% in the last 30 days. Investors should monitor whether this sale precedes further deterioration, given the severe revenue collapse and ongoing losses, or represents a modest portfolio adjustment at a near-term peak.

CRSP CEO Kulkarni sells 18,360 shares at $55.20 as stock down 46.2% from 52-week high; recent track record at ticker shows 2-of-2 prior 90-day sales well-timed.

Kulkarni, CRSP's Chief Executive Officer, sold 18,360 shares on 2025-02-19 at $55.20 (a transaction value of $1,013,563.80). The sale reduces his holdings by 9.7%, from 190.0K shares to 171.6K shares. The stock is currently trading at $47.91, which is 46.2% below its 52-week high of $89.12. Within his CRSP-specific trading history, Kulkarni has completed 5 prior trades at this ticker; his 2 measurable prior sales both delivered negative 90-day returns (-29.4% and -28.4%), meaning both preceded further declines. His broader cross-ticker track record shows a 100.00% well-timed rate on 20 prior sells, with an average 90-day return of -19.2%, indicating a pattern of selling before subsequent weakness. The company's fundamentals are stressed: annual revenue growth is -90.0%, net income was $-85.9M in the most recent year, and the latest quarterly revenue of $602.0K underscores a steep contraction. The convergence of CEO liquidation during significant drawdown, a demonstrated sell-timing pattern both at this ticker and across his broader trading history, and severe revenue and profitability deterioration, signals material weakness.

CRSP CEO Kulkarni sells 18,568 shares for $1.0M; stock -90% revenue YoY, unprofitable, down 40.5% from 52-week high

Samarth Kulkarni, CEO of CRSP, executed 2 separate sales totaling 18,568 shares for $1,006,580.40 on 2025-02-18 and 2025-02-19 at blended average price $54.21, reducing holdings by 8.9% to 189,973 shares post-transaction. The timing coincides with severe operational deterioration: annual revenue declined 90.0%, quarterly revenue stands at $602,000.00 on net income of $-85,942,000.00, and the stock has fallen 40.5% from its 52-week high. Kulkarni's prior sales at CRSP show a 100% well-timed pattern at the 90-day mark (3 of 3 prior sells preceded declines), and his cross-ticker track record reflects a 100.00% well-timed rate on 20 prior sells. This sale, however, occurs in a context of extreme fundamental weakness and substantial unrealized loss from current levels ($53.02 vs. $54.21 transaction price).

CEO Kulkarni Samarth sold 15,000 CRSP shares at $55.10 on 2024-12-02 (826.6K); stock now -42.6% from 52-week high.

CEO Kulkarni Samarth sold 15,000 shares at $55.10, reducing holdings by 7.6% to 181.5K shares. The sale occurred near the stock's 52-week high relative to current price ($51.14 is -42.6% from the $89.12 peak), and his prior trades at CRSP show a 100% well-timed sell rate at the 90-day mark across 3 measurable trades (average 90d return -3.3% to -17.0%), suggesting a pattern of selling before declines. His broader cross-ticker track record shows a 94.44% well-timed sell rate with average 90d return of -17.0%, indicating consistent success in exiting positions ahead of pullbacks. Against this backdrop, the timing of this $55.10 sale relative to the current $51.14 price, combined with the company's unprofitable status (annual net income $-85.9M) and a stock down from recent highs, may warrant investor scrutiny of near-term catalysts and the fundamental outlook.

CEO Kulkarni sells 30,000 CRSP shares (13.2% of holdings) for $1.7M at $55.62 avg; stock now $49.79, down 44.1% from 52-week high.

Kulkarni executed 2 separate sales totaling 30,000 shares for $1,668,678.36 at an average price of $55.62 on 2024-11-11, reducing his holdings by 13.2% to 196,540 shares. The transaction occurred when CRSP traded significantly above its current price of $49.79, positioning the sale well ahead of the stock's subsequent decline toward the 52-week low. His prior 5 CRSP-specific sales were all well-timed at the 90-day mark, and his cross-ticker track record shows a 89.47% well-timed rate on 19 prior sells, indicating a consistent pattern of selling before downturns. Against this backdrop, the timing of this sale relative to the stock's current position represents a continuation of historically accurate directional execution, despite the company's profitability challenges (full-year net income was negative, latest quarterly revenue was $602.0K).